Gene to Health Limited primarily focuses on developing multi-omics predictive models for common disease risks, conducting biomedical big data analysis and modeling, and providing bioinformatics research services.  We are a pioneer in Asia focused on polygenic scoring technology, leveraging millions of disease-related genetic variants and other omics data to predict over 1000 traits and diseases. Our core product suite, G2H, provides personalized health management solutions in one platform, including risk assessments for chronic diseases, dietary optimization, lifestyle advisory, and cancer risk prediction. We aim to revolutionize disease prevention and improve early disease intervention by integrating advanced genomic analysis, ML and AI.

我們是來自香港大學醫學院 (HKU Med) 的博士創業糰隊，擁有以Polygenic Scoring （多基因風險評分，PGS）的核心技術，基因智健（G2H）平颱是我們開髮的核心産品。該平颱主要利用基於多組學大數據的統計機器學習模型分析用戶數據，從而預測和評估上韆種種人類疾病風險和健康錶型，爲您的健康人生保駕護航。